Voluntary announcement h share repurchase plan
Filed with HKEX · Stock code 6872 · · 2 pages · English
Summary by 6ix AI
TenNor Therapeutics Suzhou Ltd. has announced a voluntary share repurchase plan for its H shares. The board intends to repurchase a maximum number of shares based on market conditions, with a total repurchase amount not exceeding a specified limit. This plan aims to reflect the company's confidence in its business outlook and is expected to create value for shareholders. The implementation of the plan will comply with relevant regulations and is subject to market conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
TenNor Therapeutics Suzhou Ltd. on 6ix
Earlier from TenNor Therapeutics Suzhou
- Articles of Association
- Poll results of the 2026 second extraordinary general meeting held on Friday, October 23, 2026 and amendments to the articles of association
- Voluntary announcement completion of enrollment of the first patient in the multi-center Phase IIb clinical trial of rifaquizinone (TNP-2092) administered via intra-articular injection for the treatment of prosthetic joint infection
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Form of proxy for 2026 second extraordinary general meeting to be held on October 23, 2026
Later from TenNor Therapeutics Suzhou
- Next Day Disclosure Returns
- Voluntary announcement development of rifaquizinone (TNP-2092) administered via intra-articular injection for the treatment of prosthetic joint infection as a priority indication
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow TenNor Therapeutics Suzhou into a list and get an email when it puts out news.
Follow TenNor Therapeutics Suzhou